Panacea Biotec Limited has informed the Exchange regarding 'Outcome of Inspection by National Centre for Public Health and Pharmacy, Hungary at manufacturing facility of material subsidiary, Panacea Biotec Pharma Limited at Baddi, Himachal Pradesh'.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Panacea Biotec has informed the exchange about the outcome of an inspection conducted by Hungary's National Centre for Public Health and Pharmacy at the manufacturing facility of its material subsidiary, Panacea Biotec Pharma Limited, located in Baddi, Himachal Pradesh. The inspection was carried out at a facility producing pharmaceutical products likely intended for export or registration in Hungary. The specific outcome — whether it was a clearance, observations, or concerns raised — has not been detailed in the headline provided. This is a routine regulatory compliance update from a foreign health authority visiting an Indian drug manufacturing site.
Investors should watch for any adverse observations or warnings from the Hungarian regulator, as this could affect product approvals or supply to the Hungarian market. The stock impact is likely limited unless the inspection outcome flags serious compliance issues or production halts.